Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension study of tozorakimab in COPD with prior exacerbations
NL-OMON60369Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- May 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial in chronic obstructive pulmonary disease (COPD) comparing Tozorakimab + standard of care with Placebo + standard of care (2 arms). Primary endpoint: Annualized rate of severe COPD exacerbation in former smokers. Started May 2023; status: completed.
02
Drugs
tozorakimab
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NL-OMON60369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60369.